Initial results from a vaccine trial reported Sept. 20 showed that Pfizer and BioNTech’s Covid-19 vaccine might be safe for use in children under 12 years old.
If you are not happy with the results below please do another search
50 search results for:
Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.
The U.S. Food and Drug Administration on Sept. 20 approved South Korean drugmaker Samsung Bioepis Co. Ltd. and Biogen Inc.’s biosimilar rival to Roche Holding AG’s blockbuster eye medicine Lucentis.
CVS Health Corp. said on Sept. 20 the company would fill as many as 25,000 clinical and retail jobs ahead of the flu season and as the United States prepares to administer booster Covid-19 vaccine shots.
Data needed to determine the advisability of booster shots of the Moderna Inc. and Johnson & Johnson Covid-19 vaccines is just weeks away, President Joe Biden’s chief medical adviser, Dr. Anthony Fauci, said on Sept. 19.
A combination of Mirati Therapeutics Inc.’s genetic mutation-targeting adagrasib and Eli Lilly and Co.’s older cancer drug Erbitux shrank tumors in 39 percent of patients with advanced colorectal cancer treated in a small trial, the company said on Sept. 19.
Advisers to the U.S. Food and Drug Administration voted on Sept. 17 to recommend Covid-19 vaccine booster shots for Americans 65 and older and those at high risk of severe illness, after overwhelmingly rejecting a call for broader approval.
Non-small cell lung cancer (NSCLC) is one of the most devestating diagnoses and highest unmet needs in the oncology space. EQRx, which intends to solve pricing and access challenges for patients, unveiled new data at the European Society for Medical Oncology (ESMO) Congress 2021 showing that it might just have the answer to NSCLC too.
Researchers at the University of Illinois at Chicago published what they are calling a “first of its kind study” that found a possible direct link between neurodegenerative diseases and the herpesvirus.
Vifor Pharma and Travere Therapeutics inked a collaboration and licensing partnership to commercialize sparsentan in Europe, Australia and New Zealand. The drug is being developed to treat FSGS and IgAN, which are rare progressive kidney diseases that are leading causes of end-stage kidney disease.